News | January 30, 2025
Piramal Pharma Q3 FY25 revenue up 13%
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
